• 1

    Howell C, Jeffers L, Hoofnagle JH, 2000. Hepatitis C in African Americans: Summary of a workshop. Gastroenterology 119 :1385–1396.

  • 2

    El-Serag HB, 2002. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35 (Suppl 2):S72–S78.

  • 3

    Mallat DB, Jeffers L, 2002. The natural history of hepatitis C in African Americans. Am J Gastroenterol 97 :520–522.

  • 4

    Abel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Thomas D, Fix AD, Strickland GT, Anwar W, Sallam I, 2000. Hepatitis C infection in a community in the Nile Delta: Population description of HCV prevalence. Hepatology 32 :111–115.

    • Search Google Scholar
    • Export Citation
  • 5

    Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E, Liddle C, 2000. Which patients with hepatitis C develop liver complications. Hepatology 31 :513–520.

    • Search Google Scholar
    • Export Citation
  • 6

    el-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A, 1996. Response to interferon alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 3 :261–264.

    • Search Google Scholar
    • Export Citation
  • 7

    Larrea E, Garcia N, Qian C, Civeira MP, Prieto J, 1996. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 23 :210–217.

    • Search Google Scholar
    • Export Citation
  • 8

    Fukuda R, Ishimura N, Ishihara S, Chowdhury A, Morlyama N, Nogami C, Miyake T, Niigaki M, Tokuda A, Satoh S, Sakai S, Akagi S, Watanabe M, Fukomoto S, 1996. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 16 :390–399.

    • Search Google Scholar
    • Export Citation
  • 9

    Osna N, Silonova G, Vilgert N, Hagina E, Kuse V, Giedraitis V, Zvirbliene A, Mauricas M, Sochnev A, 1997. Chronic hepatitis C: T-helper1/T-helper2 imbalance could cause virus persistence in peripheral blood. Scand J Clin Lab Invest 57 :703–710.

    • Search Google Scholar
    • Export Citation
  • 10

    Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Doi Y, Yamada A, Oshikawa O, Matsuzawa Y, 1999. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J Hepatol 30 :1–7.

    • Search Google Scholar
    • Export Citation
  • 11

    Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW, 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94 :3195–3199.

    • Search Google Scholar
    • Export Citation
  • 12

    Knight JC, Kwiatkowski D, 1999. Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Proc Assoc Am Physicians 111 :290–298.

    • Search Google Scholar
    • Export Citation
  • 13

    Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenfelde KH, Rittner C, 1998. Tumor necrosis factor alpha promoter polymorphism at position −238 is associated with chronic active hepatitis C infection. J Med Virol 54 :173–177.

    • Search Google Scholar
    • Export Citation
  • 14

    Hurme M, Lahdenpohja N, Santtila S, 1998. Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Ann Med 30 :469–473.

    • Search Google Scholar
    • Export Citation
  • 15

    Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV, 1997. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24 :1–8.

    • Search Google Scholar
    • Export Citation
  • 16

    Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV, 1998. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66 :1014–1020.

    • Search Google Scholar
    • Export Citation
  • 17

    Vidigal PG, Germer JJ, Zein NN, 2002. Polymorphisms in the interleukin-10, tumor necrosis factor-α, and transforming growth factor-β1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 36 :271–277.

    • Search Google Scholar
    • Export Citation
  • 18

    Brinkman BM, Huizinga TW, Kurban SS, van der Velde EA, Schreuder GM, Hazes JM, Breedveld FC, Verweij CL, 1997. Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 36 :516–521.

    • Search Google Scholar
    • Export Citation
  • 19

    Hamann A, Mantzoros C, Vidal-Puig A, Flier JS, 1995. Genetic variability in the TNF-alpha promoter is not associated with type II diabetes mellitus (NIDDM). Biochem Biophys Res Comm 211 :833–839.

    • Search Google Scholar
    • Export Citation
  • 20

    D’Alfonso S, Richiardi PM, 1994. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 39 :150–154.

    • Search Google Scholar
    • Export Citation
  • 21

    Zimmerman PA, Guderian RH, Nutman TB, 1996. A new TNFA promoter allele identified in South American Blacks. Immunogenetics 44 :485–486.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ETHNIC DIFFERENCES IN POLYMORPHISMS OF TUMOR NECROSIS FACTOR-α, INTERLEUKIN-10, AND TRANSFORMING GROWTH FACTOR-β1 GENES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION

View More View Less
  • 1 Division of Gastroenterology, Hepatology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota; Cairo Liver Center, Cairo, Egypt; School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Ethnic differences in the outcome of hepatitis C have been described. Our aim was to investigate ethnic differences in the distribution of genotypes associated with polymorphisms of the tumor necrosis factor-α promoter, interleukin-10 promoter, and transforming growth factor-β1 leader sequence in patients with hepatitis C. Genomic DNA was obtained from 71 Egyptians and 67 Caucasians (hepatitis C and control patients). Amplification of appropriate gene segments was followed by direct sequencing. Infrequently occurring polymorphisms were identified at positions −244 and −77 of the tumor necrosis factor-α promoter and at positions −851 and −657 of the interlukin-10 promoter. The G/A genotype associated with tumor necrosis factor-α promoter positions −376 and −244 was more frequent in Egyptians (P =0.001 and P =0.004, respectively). The −244 G/A genotype occurred only in healthy Egyptians (P =0.024). Thus, ethnic differences in the distribution of genotypes of the tumor necrosis factor-α promoter exist, which may have clinical implications on the outcome of hepatitis C.

Author Notes

Reprint requests: Nizar N. Zein, Division of Gastroenterology, Hepatology and Internal Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, Telephone: 216-444-6126, Fax: 216-445-5477, E-mail: zeinn@ccf.org.
Save